2,018 Shares in Gilead Sciences, Inc. $GILD Acquired by Jacobsen Capital Management

Jacobsen Capital Management bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, HoldingsChannel reports. The firm bought 2,018 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

Other hedge funds have also modified their holdings of the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter valued at about $25,000. Activest Wealth Management raised its position in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the second quarter valued at approximately $27,000. Goodman Advisory Group LLC bought a new stake in Gilead Sciences in the first quarter worth approximately $29,000. Finally, Colonial Trust Advisors grew its position in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on GILD shares. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. BMO Capital Markets upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a report on Tuesday, August 19th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $121.14.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company’s stock, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,500 shares of company stock worth $8,281,540. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 0.8%

Shares of NASDAQ GILD opened at $124.08 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $85.60 and a twelve month high of $124.61. The company’s fifty day moving average is $115.35 and its 200-day moving average is $110.71. The stock has a market cap of $153.96 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 0.84 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the firm posted $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.